Dabrafenib–Trametinib Plus 131I for Metastatic Radioactive Iodine–Refractory BRAF p.V600E–Mutated Differentiated Thyroid Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E Mutated Differentiated thyroid Cancer
Clin. Cancer Res 2023 Apr 19;[EPub Ahead of Print], S Leboulleux, C Do Cao, S Zerdoud, M Attard, C Bournaud, L Lacroix, D Benisvy, D Taïeb, S Bardet, M Terroir-Cassou-Mounat, N Anizan, E Bouvier-Morel, L Lamartina, G Lion, S Betrian, C Sajous, A Schiazza, ME Garcia, R Ciappuccini, M Schlumberger, A Al Ghuzlan, Y Godbert, I BorgetFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.